2025欧洲肿瘤内科学会年会(ESMO Congress 2025)将于欧洲中部夏令时间10月17日-21日在德国柏林举行。7月25日,ESMO官网已公布常规摘要题目及作者信息。
今年入选的常规摘要中,中国研究为35项。其中,优选论文专场(Proffered Paper Session)有14项,比2024年增加9项;迷你口头专场(Mini Oral Session)有19项;此外,教育专场也有2项入选。
【肿瘤资讯】特此整理了常规摘要的中国之声列表(排名不分先后),以表尊敬及祝贺。LBA的内容预计于9月20日公布,敬请期待!

肺癌
摘要号:1818MO
摘要类型:Mini oral
讲者:Suyu Wang
英文标题:Surgery versus radiotherapy after induction therapy with serplulimab combined with chemotherapy for unresectable stage IIIB-IIIC non-small cell lung cancer: a randomized controlled, open-label, phase 2 trial
中文标题:不可切除IIIB-IIIC期非小细胞肺癌经斯鲁利单抗联合化疗诱导治疗后手术对比放疗的随机对照、开放性II期临床试验
摘要号:1848MO
摘要类型:Mini oral
讲者:程颖,吉林省肿瘤医院(Ying Cheng)
英文标题:Phase 2 Study of Firmonertinib in Patients with Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer (mNSCLC) with EGFR Exon 20 Insertion (Ex20ins) Mutations
中文标题:伏美替尼治疗经治晚期/转移性非小细胞肺癌(mNSCLC)伴EGFR外显子20插入(Ex20ins)突变患者的II期研究
消化系统肿瘤
摘要号:1469MO
摘要类型:Mini oral
讲者:孙惠川,复旦大学附属中山医院(Hui-Chuan Sun)
英文标题:Liver resection versus continued atezolizumab plus bevacizumab (atezo/bev) in locally advanced hepatocellular carcinoma (HCC) after atezo/bev treatment (TALENTop): a multicenter, open-label, randomized phase III trial.
中文标题:对于经阿替利珠单抗+贝伐珠单抗 (atezo/bev) 治疗后的局部晚期肝细胞癌 (HCC) 患者,比较肝切除术与继续atezo/bev治疗 (TALENTop):一项多中心、开放标签、随机III期试验
摘要号:1470MO
摘要类型:Mini oral
讲者:周俭,复旦大学附属中山医院(Jian Zhou)
英文标题:Perioperative Camrelizumab plus Rivoceranib in Resectable Hepatocellular Carcinoma (CARES-009): A Randomized, Multicenter, Phase 3 Trial
中文标题:围手术期卡瑞利珠单抗联合阿帕替尼用于可切除肝细胞癌的随机、多中心、III期临床试验(CARES-009)
摘要号:2215MO
摘要类型:Mini oral
讲者:王理伟,上海交通大学医学院附属仁济医院(Liwei Wang)
英文标题:HRS-4642 Combined with Gemcitabine and Nab-paclitaxel in KRAS-G12D Mutant Advanced Pancreatic Cancer: A Phase 1b/2 Study
中文标题:HRS-4642联合吉西他滨和白蛋白结合型紫杉醇治疗KRAS-G12D突变晚期胰腺癌的1b/2期研究
乳腺癌
摘要号:297MO
摘要类型:Mini oral
讲者:李培勇,南方医科大学附属广东省人民医院( Peiyong Li)
英文标题:Timing of Pegfilgrastim Administration and Pegfilgrastim-Induced Bone Pain: A Prospective, Randomized Phase 3 Trial
中文标题:培非格司亭的给药时机与培非格司亭诱导的骨痛:一项前瞻性、随机化 3 期试验
泌尿生殖系统肿瘤
摘要号:2592MO
摘要类型:Mini Oral
讲者:叶定伟,复旦大学附属肿瘤医院(Dingwei Ye)
英文标题:Fruquintinib (FRUQ) plus sintilimab (SIN) versus axitinib (AXI) or everolimus (EVE) monotherapy as 2L treatment in pts with locally advanced or metastatic renal cell carcinoma (RCC): results from phase 3 part of a randomized, open-label, active-controlled phase 2/3 study (FRUSICA-2)
中文标题:呋喹替尼(FRUQ)联合信迪利单抗(SIN)对比阿昔替尼(AXI)或依维莫司(EVE)单药治疗局部晚期或转移性肾细胞癌(RCC)患者的二线疗法:一项随机、开放标签、阳性对照II/III期研究(FRUSICA-2)的III期阶段结果
中枢神经系统肿瘤
摘要号:656O
摘要类型:Proffered paper
讲者:Huang Qingting
英文标题:Proton versus Carbon Ion Radiotherapy in Skull Base Chordoma and Chondrosarcoma: Initial Clinical Outcomes from a Phase II Randomized Trial"
中文标题:质子与碳离子放射治疗颅底脊索瘤和软骨肉瘤的初步临床结果:一项II期随机对照试验
摘要号:657O
摘要类型:Proffered paper
讲者:李文斌,首都医科大学附属北京天坛医院(Wenbin Li)
英文标题:A randomized, controlled, multicenter, phase II/III clinical study to evaluate the safety and efficacy of chlorogenic acid for injection in the treatment of recurrent grade IV glioblastoma (GBM)
中文标题:一项评估注射用绿原酸治疗复发性IV级胶质母细胞瘤(GBM)安全性及有效性的随机、对照、多中心II/III期临床研究
摘要号:659O
摘要类型: Proffered paper
讲者:郑媚美,广东省人民医院(Meimei Zheng)
英文标题:Molecular diagnosis and management of leptomeningeal metastases with evolving therapeutic paradigm in advanced lung cancer
中文标题:晚期肺癌软脑膜转移的分子诊断与综合管理:治疗新模式的演进
摘要号:661MO
摘要类型:Mini Oral
讲者:李文斌 首都医科大学附属北京天坛医院(Wenbin Li)
英文标题:Update on the phase II study: to explore the efficacy and safety of luvometinib (FCN-159) in recurrent or progressive pediatric low-grade glioma with MAPK pathway-activated
中文标题:II期研究进展更新:探索luvometinib(FCN-159)在MAPK通路激活的复发性或进展性儿童低级别胶质瘤中的疗效与安全性
摘要号:665MO
摘要类型:Mini Oral
讲者:王郑封,郑州大学第一附属医院(Zhengfeng Wang)
英文标题:DNA methylation-based epigenetic signatures for classification and non-invasive diagnosis of gliomas
中文标题:基于DNA甲基化的表观遗传特征用于胶质瘤分类及无创诊断
头颈肿瘤
摘要号:1063O
摘要类型: Proffered paper
讲者:苗菁菁,中山大学肿瘤防治中心(Jingjing Miao)
英文标题:Concurrent Chemoradiotherapy with/without Adjuvant Capecitabine in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Controlled Phase III Trial
中文标题:同步放化疗或联合卡培他滨辅助治疗局部晚期鼻咽癌:一项随机对照 III 期试验
摘要号:1319O
摘要类型: Proffered paper
讲者:何悦,上海交通大学医学院附属第九人民医院(Yue He)
英文标题:Perioperative camrelizumab plus chemotherapy in locally advanced squamous cell carcinoma of the head and neck (CAMORAL): A multicenter, open-label, randomized, phase II Study
中文标题:卡瑞利珠单抗联合化疗围手术期治疗局部晚期头颈部鳞癌(CAMORAL):一项多中心、开放标签、随机对照 Ⅱ 期研究
摘要类型:Educational session
讲者:陈明远,中山大学肿瘤防治中心(Mingyuan Chen)
英文标题:The role of consolidation and ablative therapy
中文标题:巩固治疗与消融术的作用
妇科肿瘤
摘要号:1063O
摘要类型:Proffered paper
讲者:李宁,中国医学科学院肿瘤医院(Ning Li)
英文标题:Fuzuloparib (FZPL) monotherapy or in combination with apatinib (APA) as first-line (1L) maintenance therapy in advanced ovarian cancer (OC): final analysis of the FZOCUS-1 trial
中文标题:氟唑帕利单药或联合阿帕替尼作为晚期卵巢癌的一线维持治疗:FZOCUS-1 试验的最终分析
在研疗法
摘要号:914O
摘要类型:Proffered paper
讲者:黄鼎智,天津医科大学肿瘤医院(Dingzhi Huang)
英文标题:HRS-7058, a KRAS G12C inhibitor (G12Ci), in advanced solid tumors with KRAS G12C mutation: a phase 1, multi-center, first-in-human study
中文标题:HRS-7058(一种KRAS G12C抑制剂)在携带KRAS G12C突变的晚期实体瘤患者中的I期、多中心、首次人体研究
摘要号:915O
摘要类型:Proffered paper
讲者:周彩存,同济大学附属东方医院(Caicun Zhou)
英文标题:KRAS G12D inhibitor HRS-4642 in patients with KRAS G12D-mutant advanced solid tumors: a phase 1 trial
中文标题:KRAS G12D抑制剂HRS-4642用于KRAS G12D突变晚期实体瘤患者的I期临床试验
摘要号:922MO
摘要类型:Mini Oral
讲者:宋正波,浙江省肿瘤医院(Zhengbo Song)
英文标题:Updated ongoing Phase I/II clinical trial results of AMT-116, a first-in-class anti-CD44v9 antibody-drug conjugate (ADC), in patients with advanced solid tumors
中文标题:AMT-116(全球首创抗CD44v9抗体偶联药物)治疗晚期实体瘤患者的I/II期临床试验最新进展
免疫疗法
摘要号:1511O
摘要类型:Proffered paper
讲者:翟优,首都医科大学附属北京天坛医院(You Zhai)
英文标题:Locoregional bispecific CAR-T cells targeting CD44 and CD133 show safety and efficacy in recurrent high-grade glioma in a first-in-human investigator-initiated trial
中文标题:靶向CD44和CD133的双特异性CAR-T细胞治疗复发性高级别胶质瘤的首个研究者发起人体试验显示安全有效
摘要号:1514O
摘要类型:Proffered paper
讲者:Xueli Bai
英文标题:First-in-human phase 1 study of TCR-T therapy targeting KRAS G12V in metastatic solid tumors
中文标题:靶向KRAS G12V的TCR-T疗法治疗转移性实体瘤的首次人体I期临床研究
血液系统肿瘤
摘要号:1243MO
摘要类型:Mini Oral
讲者:王杰松,福建省肿瘤医院(Jiesong Wang)
英文标题:Risk Stratification for Diffuse Large B-Cell Lymphoma by Integrating Interim 18F-FDG PET-CT Analysis and the NCCN-IPI: A Multicentre Retrospective Study
中文标题:通过整合中期18F-FDG PET-CT分析和NCCN-IPI研究对弥漫性大B细胞淋巴瘤进行风险分层:一项多中心回顾性研究
摘要号:245MO
摘要类型:Mini Oral
讲者:李志铭,中山大学肿瘤防治中心(Zhi-Ming Li)
英文标题:Combination of Mitoxantrone Hydrochloride Liposome with Chidamide in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma: Updated Results of the Phase II Study
中文标题:盐酸米托蒽醌脂质体联合西达本胺治疗复发或难治性外周T细胞淋巴瘤的II期研究结果更新
摘要号:1246MO
摘要类型:Mini Oral
讲者:Sicong Zhang
英文标题:Single-Cell Atlas of Circulating Immunity identifies shared specific DLBCL signatures for predicting Response to R-CHOP and Anti-CD19 CAR T Therapies
中文标题:单细胞循环免疫图谱识别共享的特异性DLBCL标记,用于预测对R-CHOP和CD19 CAR-T的治疗反应
摘要号:1247MO
摘要类型:Mini Oral
讲者:孙聪,天津医科大学肿瘤医院(Cong Sun)
英文标题:Molecular Landscape of Distinct Follicular Lymphoma Histologic Grades: Insights from Genomic and Transcriptome Analyses
中文标题:不同滤泡性淋巴瘤组织学分级的分子图谱:来自基因组和转录组分析的见解
摘要号:1248MO
摘要类型:Mini Oral
讲者:Xinyu Sun
英文标题:Changes in Peripheral Blood Leukemia Stem Cells, Immune Cell Subsets, Cytokines, and Cellular Differentiation Status Before and After Venetoclax-Containing Regimen Treatment for Acute Myeloid Leukemia
中文标题:含维奈托克方案治疗急性髓系白血病前后外周血白血病干细胞、免疫细胞亚群、细胞因子和细胞分化状态的变化
摘要号:1240O
摘要类型:Proffered paper
讲者:王亮,首都医科大学附属北京同仁医院(Liang Wang)
英文标题:CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory Large B-cell Lymphoma: a Prospective, Single-arm, Single-center, Phase 2 Clinical Trial
中文标题:CD19/CD22双特异性CAR-T细胞治疗复发性/难治性大B细胞淋巴瘤:一项前瞻性、单组、单中心、II期临床试验
摘要号:1241O
摘要类型:Proffered paper
讲者:Lei Zhang
英文标题:Anti-PD-1-Antibody (Tislelizumab) Combined with Chidamide, Lenalidomide and Etoposide for the treatment of refractory/relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single -Arm, Phase II Trial
中文标题:抗PD-1抗体(替雷利珠单抗)联合西达本胺、来那度胺和依托泊苷治疗复发/难治性结外鼻型自然杀伤/T细胞淋巴瘤(R/R ENKTL):一项前瞻性、多中心、单臂、II期试验的初步结果
肉瘤
摘要号:2689MO
摘要类型:Mini Oral
讲者:张星,中山大学肿瘤防治中心(Xing Zhang)
英文标题:A phase II trial of the combination of Chidamide and Toripalimab in patients with advanced sarcoma
中文标题:西达本胺与特瑞普利单抗联合治疗晚期肉瘤患者的 II 期临床试验
摘要号:2684O
摘要类型:Proffered paper
讲者:谢璐,北京大学人民医院(Lu Xie)
英文标题:ARTEMIS-002: A Phase 2 Study of HS-20093 in Patients with Relapsed or Refractory Sarcomas
中文标题:ARTEMIS-002:HS-20093 治疗复发或难治性肉瘤患者的II期研究
神经内分泌肿瘤
摘要号:2987O
摘要类型:Proffered paper
讲者:高明,天津市人民医院(Ming Gao)
英文标题:Efficacy and Safety of Dabrafenib Plus Trametinib (D+T) in Patients With Radioactive Iodine (RAI)-Refractory BRAF V600-Mutant Differentiated Thyroid Cancer (DTC)
中文标题:达拉非尼联合曲美替尼(D+T)治疗放射性碘(RAI)难治性BRAF V600突变分化型甲状腺癌(DTC)患者的疗效与安全性
摘要号:1707MO
摘要类型:Mini Oral
讲者:赵春华,中国医学科学院基础医学研究所(Chuanhua Zhao)
英文标题:A Phase 2 Dose Expansion Study of ZG006, a Trispecific T Cell Engager Targeting DLL3/DLL3/CD3, as Monotherapy in Patients with Refractoy Neuroendocrine Carcinoma
中文标题:ZG006(一种靶向 DLL3/DLL3/CD3 的三特异性 T 细胞接合剂)单药治疗难治性神经内分泌癌的II期剂量扩展研究
摘要号:1708MO
摘要类型:Mini Oral
讲者:Sisi Ye
英文标题:ZG005 in combination with etoposide and cisplatin for the first-line treatment of advanced neuroendocrine carcinoma
中文标题:ZG005 联合依托泊苷和顺铂用于晚期神经内分泌癌一线治疗
摘要号:2988MO
摘要类型:Mini Oral
讲者:刘嘉烨,四川大学华西医院(Jiaye Liu)
英文标题:Patient-Derived Organoids Predict Clinical Response and Guide Personalized Therapy in Advanced Thyroid Cancer
中文标题:患者源性类器官预测晚期甲状腺癌的临床反应并指导个性化治疗
其他
摘要类型:Educational session
讲者:Brigette B. Ma (Sha Tin, Hong Kong SAR, China)
英文标题:Nasal/paranasal cavity cancers: Clinical perspectives
中文标题:鼻腔癌及鼻窦癌——临床视角
如有遗漏,欢迎留言补充!
排版编辑:肿瘤资讯-tcz